T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new class of therapeutics for cancer. based on their remarkable potency in blood cancers. Since the first clinical reports of their efficacy emerged 7 years ago. investigators have focused on the mechanisms and properties that make CARs effective or toxic. https://stilleners.shop/product-category/suspension-system/